The first and only BCMA-targeting antibody-drug conjugate for appropriate patients with relapsed/refractory multiple myeloma1
• Studied as a single agent in patients refractory to an immunomodulatory agent and a proteasome inhibitor and an anti-CD38 antibody1
• Deep and durable responses. 32% overall response rate (31/97; 97.5% Cl: 22%, 44%) in a patient population with a median 7 lines of prior therapy, and with median duration of response of 11 months (95% Cl: 4.2, not reached)1
• Manageable safety profile1
• 30 minutes every 3 weeks1
1. BLENREP Summary of Product Characteristics.
Product Highlight - Blenrep
16 Mar 2022